GANX (Gain Therapeutics) Research & Development: $10.72 Mil (TTM As of Mar. 2026)


GANX Gain Therapeutics Inc GANX
31 GF Score
Price $1.72
! 2 Warning Signs
View Full Analysis

What is Gain Therapeutics Research & Development?

Gain Therapeutics GANX -1.15% 31 Research & Development is $10.72 Mil as of Mar. 2026. GuruFocus rates GANX with a GF Score™ of 31/100. The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Gain Therapeutics's Research & Development for the three months ended in Mar. 2026 was $2.76 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $10.72 Mil.

Gain Therapeutics  (NAS:GANX) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Gain Therapeutics Research & Development Related Terms

Gain Therapeutics Research & Development Historical Data

* Premium members only.

The historical data trend for Gain Therapeutics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gain Therapeutics Research & Development Chart

Gain Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 7.16 8.38 11.52 10.79 10.21

Gain Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.26 2.76 2.85 2.35 2.76
GANX
31GF Score
Gain Therapeutics Inc GANX
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gain Therapeutics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $10.72 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $10.72 Mil mean?
Gain Therapeutics (GANX) has a Research & Development of $10.72 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Gain Therapeutics and its competitors.
Is Gain Therapeutics' Research & Development too high?
Gain Therapeutics' current Research & Development is $10.72 Mil. Overall, Gain Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Gain Therapeutics' Research & Development compare to EXOZ and HYFT?
Gain Therapeutics' Research & Development of $10.72 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Gain Therapeutics and its competitors. Gain Therapeutics's current Research & Development is $10.72 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gain Therapeutics stock overvalued right now?
Gain Therapeutics (GANX) has a current Research & Development of $10.72 Mil. The current Research & Development is $10.72 Mil. Gain Therapeutics' overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Gain Therapeutics (GANX), the current Research & Development is $10.72 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Gain Therapeutics Business Description

Address 4800 Montgomery Lane, Suite 220, Bethesda, MD, USA, 20814
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.
31GF Score

Get the complete analysis for GANX

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.72
Price